Sarasin & Partners LLP Sells 43,136 Shares of Healthpeak Properties, Inc. $DOC

Sarasin & Partners LLP lowered its position in shares of Healthpeak Properties, Inc. (NYSE:DOC) by 34.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,206 shares of the real estate investment trust’s stock after selling 43,136 shares during the period. Sarasin & Partners LLP’s holdings in Healthpeak Properties were worth $1,759,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DOC. GAMMA Investing LLC lifted its stake in Healthpeak Properties by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 17,933 shares of the real estate investment trust’s stock worth $384,000 after purchasing an additional 3,162 shares in the last quarter. Versant Capital Management Inc grew its position in shares of Healthpeak Properties by 24.3% during the 2nd quarter. Versant Capital Management Inc now owns 5,633 shares of the real estate investment trust’s stock valued at $121,000 after purchasing an additional 1,102 shares in the last quarter. Hilltop National Bank increased its holdings in shares of Healthpeak Properties by 2,500.0% in the second quarter. Hilltop National Bank now owns 2,080 shares of the real estate investment trust’s stock worth $45,000 after purchasing an additional 2,000 shares during the period. CX Institutional increased its holdings in shares of Healthpeak Properties by 6.1% in the second quarter. CX Institutional now owns 11,003 shares of the real estate investment trust’s stock worth $235,000 after purchasing an additional 633 shares during the period. Finally, Redwood Investment Management LLC raised its position in shares of Healthpeak Properties by 8.3% in the first quarter. Redwood Investment Management LLC now owns 44,438 shares of the real estate investment trust’s stock worth $730,000 after buying an additional 3,410 shares in the last quarter. Institutional investors own 93.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DOC. Morgan Stanley reissued an “equal weight” rating and set a $22.00 price objective (up from $20.00) on shares of Healthpeak Properties in a research note on Thursday, June 11th. Wall Street Zen upgraded Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Raymond James Financial assumed coverage on Healthpeak Properties in a report on Wednesday, June 17th. They issued a “market perform” rating on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Healthpeak Properties in a research report on Wednesday. Finally, Cantor Fitzgerald boosted their price objective on Healthpeak Properties from $20.00 to $23.00 and gave the stock a “neutral” rating in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.97.

Insider Buying and Selling at Healthpeak Properties

In other news, insider Scott R. Bohn sold 10,989 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the sale, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. The trade was a 59.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.23% of the company’s stock.

Healthpeak Properties Price Performance

DOC opened at $21.10 on Friday. The company has a current ratio of 3.02, a quick ratio of 2.96 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $14.55 billion, a P/E ratio of 60.30, a PEG ratio of 3.37 and a beta of 1.01. The stock has a 50-day moving average price of $21.15 and a 200-day moving average price of $18.78. Healthpeak Properties, Inc. has a 12-month low of $15.70 and a 12-month high of $22.95.

Healthpeak Properties (NYSE:DOC) last announced its quarterly earnings data on Tuesday, August 4th. The real estate investment trust reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.05. The company had revenue of $771.58 million for the quarter, compared to analysts’ expectations of $725.64 million. Healthpeak Properties had a return on equity of 2.79% and a net margin of 8.24%.Healthpeak Properties’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period last year, the firm posted $0.46 EPS. Healthpeak Properties has set its FY 2026 guidance at 1.730-1.770 EPS. Equities analysts predict that Healthpeak Properties, Inc. will post 1.76 earnings per share for the current fiscal year.

Healthpeak Properties Announces Dividend

The firm also recently declared a monthly dividend, which will be paid on Friday, September 25th. Shareholders of record on Monday, September 14th will be paid a dividend of $0.1017 per share. The ex-dividend date of this dividend is Monday, September 14th. This represents a c) annualized dividend and a dividend yield of 5.8%. Healthpeak Properties’s dividend payout ratio (DPR) is 348.57%.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.